New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation-Reference-Cited by-同舟云学术

New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation

Published:2014-12-31 Issue:4 Volume:62 Page:680-686
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Gaziev Javid¹,Isgrò Antonella¹,Mozzi Alessia Francesca²,Petain Aurèlie³,Nguyen Laurent³,Ialongo Cristiano²,Dinallo Vincenzo²,Sodani Pietro¹,Marziali Marco¹,Andreani Marco¹,Testi Manuela¹,Paciaroni Katia¹,Gallucci Cristiano¹,De Angelis Gioia¹,Alfieri Cecilia¹,Ribersani Michela¹,Lucarelli Guido¹

Affiliation:

1. International Center for Transplantation in Thalassemia and Sickle Cell Anemia; Mediterranean Institute of Hematology; Policlinico Tor Vergata; Rome Italy

2. Department of Laboratory Medicine; Policlinico Tor Vergata; Rome Italy

3. Istitut de Recherche Pierre Fabre; Toulouse France

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference45 articles.

1. Improved survival of children and adolescents with sickle cell disease;Quinn;Blood,2010

2. Cardiopulmonary complications leading to premature death in adult patients with sickle cell disease;Fitzhugh;Am J Hematol,2010

3. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease;Hulbert;Blood,2011

4. Bone marrow transplantation for sickle cell disease;Walters;N Engl J Med,1996

5. Hematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium;Vermylen;Bone Marrow Transplant,1998

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update review of new therapies in sickle cell disease: the prospects for drug combinations;Expert Opinion on Pharmacotherapy;2024-01-22

2. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions;Expert Opinion on Drug Metabolism & Toxicology;2023-02-01

3. Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease;Journal of Clinical Medicine;2022-07-03

4. Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?;Frontiers in Pediatrics;2022-04-07

5. Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let’s Clear Up That Case With Some Controls;Journal of Pediatric Hematology/Oncology;2021-03-03